Zydus Lifesciences Limited has announced the dissolution of its French subsidiary Ampliman 2, effective January 9, 2026, as part of a corporate restructuring that will not affect the pharmaceutical company's business operations. The announcement was made through a regulatory filing under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subsidiary Structure and Dissolution Details

Ampliman 2, France, operated as a wholly owned subsidiary of Zydus MedTech (France) S.A.S., which itself is a step-down wholly owned subsidiary of Zydus Lifesciences Limited . The dissolution was executed without liquidation, ensuring a smooth transfer of corporate assets and obligations.

Asset and Liability Transfer

Upon dissolution, all assets and liabilities of Ampliman 2 have been transferred to Zydus MedTech (France) S.A.S., ensuring continuity of operations and maintaining the company's European business structure. This transfer mechanism allows for the consolidation of resources while preserving operational capabilities within the French market.

Business Impact Assessment

The company has explicitly stated that the dissolution of Ampliman 2 will not impact its business operations. This indicates that the subsidiary's functions have been effectively integrated into the parent French entity or were non-critical to the overall business strategy. The restructuring appears to be aimed at simplifying the corporate structure while maintaining operational efficiency.

Regulatory Compliance

The dissolution announcement was signed by Dhaval N. Soni, Company Secretary and Compliance Officer, ensuring proper regulatory disclosure. The company maintains its registered office at Zydus Corporate Park in Ahmedabad, Gujarat, and continues to operate under CIN L24230GJ1995PLC025878. This corporate action demonstrates the company's commitment to transparent communication with stakeholders regarding structural changes in its international operations.

Zydus Lifesciences Limited has announced the dissolution of its wholly owned subsidiary Auroralux S.A.S., Luxembourg, effective December 31, 2025. The pharmaceutical company informed stock exchanges about this corporate restructuring move under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

Corporate Structure Changes

The dissolution involves a step-down subsidiary arrangement where Auroralux S.A.S. is a wholly owned subsidiary of Zydus MedTech (France) S.A.S., which itself is a step-down wholly owned subsidiary of Zydus Lifesciences Limited. The company received official intimation on January 2, 2026, due to festive New Year holidays.

Asset Transfer and Subsidiary Realignment

Upon dissolution, all assets and liabilities of Auroralux S.A.S. will be transferred to Zydus MedTech (France) S.A.S. This transfer includes the dissolved entity's investments in Amplitude Surgical S.A.S. As a result of this restructuring, Amplitude Surgical S.A.S. will become a wholly owned subsidiary of Zydus MedTech (France) S.A.S.

The asset transfer mechanism ensures continuity of operations and maintains the pharmaceutical company's European business interests through its French subsidiary structure.

Business Impact Assessment

Zydus Lifesciences has explicitly stated that the dissolution of Auroralux S.A.S. will not impact the company's business operations. This indicates that the move represents an internal corporate restructuring rather than a strategic business exit from any particular market or therapeutic area.

Regulatory Compliance

The announcement was made in compliance with regulatory requirements, with Company Secretary and Compliance Officer Dhaval N. Soni signing the disclosure document. The communication was sent to both BSE Limited and National Stock Exchange of India Limited, ensuring full transparency with stakeholders about the corporate structural changes.